Free Trial

Bahl & Gaynor Inc. Reduces Stock Holdings in Chemed Co. (NYSE:CHE)

Chemed logo with Medical background
Remove Ads

Bahl & Gaynor Inc. lowered its holdings in shares of Chemed Co. (NYSE:CHE - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,909 shares of the company's stock after selling 785 shares during the quarter. Bahl & Gaynor Inc. owned 0.11% of Chemed worth $8,958,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CHE. FMR LLC boosted its holdings in Chemed by 23.8% during the 3rd quarter. FMR LLC now owns 238,616 shares of the company's stock valued at $143,401,000 after acquiring an additional 45,917 shares during the period. Principal Financial Group Inc. raised its position in Chemed by 114.1% during the 4th quarter. Principal Financial Group Inc. now owns 74,658 shares of the company's stock valued at $39,554,000 after purchasing an additional 39,791 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Chemed by 25.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 146,017 shares of the company's stock valued at $87,752,000 after purchasing an additional 29,445 shares in the last quarter. Aureus Asset Management LLC raised its position in Chemed by 3,147.2% during the 3rd quarter. Aureus Asset Management LLC now owns 29,939 shares of the company's stock valued at $17,993,000 after purchasing an additional 29,017 shares in the last quarter. Finally, Boston Trust Walden Corp raised its position in Chemed by 10.0% during the 4th quarter. Boston Trust Walden Corp now owns 242,172 shares of the company's stock valued at $128,303,000 after purchasing an additional 22,105 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company's stock.

Remove Ads

Insider Transactions at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $593.67, for a total value of $1,187,340.00. Following the completion of the transaction, the chief executive officer now directly owns 102,679 shares of the company's stock, valued at approximately $60,957,441.93. The trade was a 1.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Brian C. Judkins purchased 145 shares of Chemed stock in a transaction dated Monday, December 30th. The stock was bought at an average cost of $519.50 per share, with a total value of $75,327.50. Following the completion of the transaction, the vice president now owns 1,678 shares in the company, valued at approximately $871,721. This represents a 9.46 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.32% of the company's stock.

Chemed Stock Performance

NYSE CHE traded up $1.51 on Friday, reaching $595.86. 124,996 shares of the stock traded hands, compared to its average volume of 99,602. The company has a fifty day moving average price of $553.87 and a 200-day moving average price of $564.10. The company has a market cap of $8.72 billion, a price-to-earnings ratio of 30.11, a PEG ratio of 2.15 and a beta of 0.43. Chemed Co. has a 12 month low of $512.12 and a 12 month high of $654.62.

Chemed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Monday, February 24th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.34%. The ex-dividend date is Monday, February 24th. Chemed's payout ratio is 10.05%.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Chemed from a "hold" rating to a "buy" rating in a research report on Friday.

View Our Latest Report on Chemed

Chemed Company Profile

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Further Reading

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Should You Invest $1,000 in Chemed Right Now?

Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

3 Bank Stocks Defying Market Turmoil—Cheap Options Trades!
Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads